Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study [PDF]
Journal of the International AIDS SocietyIntroduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes
Erik Sörstedt +9 more
doaj +2 more sources
Frontiers in Oncology, 2021 Lamivudine, also widely known as 3TC belongs to a family of nucleotide/nucleoside analogues of cytidine or cytosine that inhibits the Reverse Transcriptase (RT) of retroviruses such as HIV.
José J. García-Trejo +2 more
doaj +1 more source
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. [PDF]
PLoS ONE, 2016 Sequential addition of tenofovir disoproxil fumarate (TDF) is often needed for patients coinfected with HIV and hepatitis B virus (HBV) who develop HBV resistance to lamivudine after combination antiretroviral therapy (cART) containing only lamivudine ...
Yu-Shan Huang +9 more
doaj +1 more source
Removal of lamivudine from synthetic solution using jamun seed (Syzygium cumini) biochar adsorbent
Emerging Contaminants, 2023 Antiviral drugs such as lamivudine have been globally identified in the environment and marked as emerging pollutants of concern due to their bioactive extremity.
Asha Ripanda +7 more
doaj +1 more source
Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. [PDF]
PLoS ONE, 2016 In the fall of 2014, an international news agency reported that patients suffering from Ebola virus disease (EVD) in Liberia were treated successfully with lamivudine, an antiviral drug used to treat human immunodeficiency virus-1 and hepatitis B virus ...
Yu Cong +35 more
doaj +1 more source
Nano Co-Crystal Embedded Stimuli-Responsive Hydrogels: A Potential Approach to Treat HIV/AIDS
Pharmaceutics, 2021 Currently, the human immunodeficiency virus (HIV) that causes acquired immunodeficiency syndrome (AIDS) can only be treated successfully, using combination antiretroviral (ARV) therapy.
Bwalya A. Witika +3 more
doaj +1 more source
EBioMedicine, 2020 : Background: We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. Methods: Open-label,
Rosa De Miguel +21 more
doaj +1 more source
Relationship of Hearing Impairment in Patients with Lamivudine Therapy: A Systematic Review and Meta-analysis [PDF]
Journal of Clinical and Diagnostic Research, 2022 Introduction: Lifelong Antiretroviral Therapy (ARVT) in patients with Human Immunodeficiency Virus (HIV) infection damages cochlea. Hearing Loss (HL) has been reported with lamivudine therapy in both HIV and/or Hepatitis B Virus (HBV) infections.
Mahesh Namdeo Belhekar, Kalpesh K Joshi
doaj +1 more source
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Viruses, 2022 Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a ...
Carmen Hidalgo-Tenorio +15 more
doaj +1 more source
Pharmaceutics, 2023 Dose recommendations for lamivudine or emtricitabine in children with HIV and chronic kidney disease (CKD) are absent or not supported by clinical data.
Tom G. Jacobs +7 more
doaj +1 more source